

**From:** Taney Hamill  
**To:** Taney Hamill  
**Date:** 6/14/05 7:00PM  
**Subject:** **WBL - Here's to Us!**

Congratulations to the following WBL Foundation Associates on their outstanding achievements and the achievements of their companies:

WBL Foundation Associate **Carol Berry**, Head of Sales/Marketing, Diagnostic Division, CIPHERGEN Biosystems ([www.ciphergen.com](http://www.ciphergen.com)), has been named **Industry Liaison for the Ovarian Cancer National Alliance's "Turn Up The Volume!" Campaign**. The Ovarian Cancer National Alliance ("OCNA") is a non-profit group launching an exciting national PR and marketing campaign to "Turn Up The Volume!" on the deadliest gynecologic cancer -- affecting 1 in 57 American women but with symptoms that are often vague and common. In Carol's new role, she will be helping with the campaign's corporate sponsorships to raise awareness of this disease for which there is currently no reliable diagnostic test. To learn more, please visit OCNA's website at [www.ovariancancer.org](http://www.ovariancancer.org) or contact **Carol Berry** at (972) 567-4023 or [cberry@ciphergen.com](mailto:cberry@ciphergen.com).

**Amylin Pharmaceuticals, Inc.** ([www.amylin.com](http://www.amylin.com)), led by WBL Foundation Associate **Ginger Graham** ([ggraham@amylin.com](mailto:ggraham@amylin.com)), President and Chief Executive Officer, announces the FDA Approval of SYMLIN (r) (pramlintide acetate) injection to be used in conjunction with insulin to treat diabetes. SYMLIN is to be used at mealtime in patients with type 2 or type 1 diabetes who have failed to achieve desired glucose control despite optimal insulin therapy. "The approval of SYMLIN, a first-in-class therapy, is a major milestone for Amylin Pharmaceuticals. It is the result of 18 years of research in diabetes," said Ginger L. Graham. In addition, the FDA approved a second drug of Amylin's called BYETTA (tm) (exenatide) injection, a compound originally isolated from the saliva of the gila monster, a lizard native to the southwest United States. BYETTA is to be used as an additional therapy for patients with Type II diabetes not achieving desired glucose control on common oral diabetes medications.

WBL Foundation Associate **Rebecca Hurley** ([rebecca.hurley@triadhospitals.com](mailto:rebecca.hurley@triadhospitals.com)) has been named General Counsel at **Triad Hospitals, Inc** ([www.triadhospitals.com](http://www.triadhospitals.com)). Her new title will be Senior Vice President and General Counsel, beginning at the end of May 2005.

WBL Foundation Associate **Judy Jones** ([jjones@siib.org](mailto:jjones@siib.org)), Director of Advancement, **The Samueli Institute for Information Biology** ([www.siib.org](http://www.siib.org)), reports that the Institute received a second year renewal of the Complementary and Alternative Medicine Research for Military Operations and Healthcare (MIL-CAM) program funded by the Department of Defense in collaboration with the Uniformed Services University of Health Sciences. The Institute's role is to solicit applications for the VET-HEAL program, and after scientific review to provide oversight to the funded protocols. An RFA and the new research application forms were posted on the Samueli webpage. The Samueli Institute for Information Biology is a non-profit, non-affiliated medical research organization supporting the scientific investigation of healing processes with information biology, and its application in health and disease.

**Susan Nedza** MD, ([snedza@cms.hhs.gov](mailto:snedza@cms.hhs.gov)) Chief Medical Officer, Region V, Centers for Medicare & Medicaid Services was honored as the 2005 Recipient of the Bill Smiley Award. This is the highest award given to an emergency physician in the state of Illinois for service, sponsored by the Illinois College of Emergency Physicians.

WBL Foundation Associate **Marcia Nusgart**, President, **Nusgart Consulting, LLC**, ([marcia@nusgartconsulting.com](mailto:marcia@nusgartconsulting.com)) was honored by the Association for Advancement of Wound Care at the recent Symposium on Advances for Wound Care in San Diego, receiving a leadership award "In recognition of [her] vision and leadership as Executive Director of the Alliance of Wound Care Stakeholders," for her work coordinating the Alliances' response to the Medicare Coverage Advisory Committee on usual care of chronic wounds, and for her role as a resource to the Office of Inspector

General and CMS on issues involving wound care.

WBL Foundation Associate **Carolyn Smeltzer** ([carolyn.smeltzer@us.pwc.com](mailto:carolyn.smeltzer@us.pwc.com)), Principal, **PriceWaterhouseCoopers** ([www.pwcglobal.com](http://www.pwcglobal.com)), is the co-author of a new book, "Chicago's Nurse Parade" published by [arcadiapublishing.com](http://arcadiapublishing.com).

\*\*\*

If you have a business or professional success that you would like to share with other WBL Foundation Associates, please e-mail the necessary information to Taney Hamill ([thamill@ebglaw.com](mailto:thamill@ebglaw.com)) or Eleanor Whitley ([ewhitley@ebglaw.com](mailto:ewhitley@ebglaw.com)). Remember, self-promotion is item number one of our Ten Best Practices for Advancing Women in Business!

C. Taney Hamill  
Chief Executive Officer  
Women Business Leaders  
of the U.S. Healthcare Industry Foundation  
1227 25th Street, N.W., Suite 700  
Washington, D.C. 20037-1175  
202-861-1835 Washington DC office  
[thamill@ebglaw.com](mailto:thamill@ebglaw.com)  
410-263-0013 Annapolis office  
410-507-0379 mobile  
[Taney\\_Hamill@comcast.net](mailto:Taney_Hamill@comcast.net)  
[www.womenleadinghealthcare.org](http://www.womenleadinghealthcare.org)

**CC:** Eleanor Whitley; Lynn Snyder